- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16:01 | Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds? | ||
| 16:01 | FDA faults Biocon plant during preapproval review | ||
| 16:01 | How influential are influencers? FDA plots study to measure power of Instagram celebs | ||
| Di | Pfizer's heart med Vyndaqel off and running thanks to diagnosis push: execs | ||
| Di | Pfizer nixes multiple Bavencio tests, plus an early Inlyta-Keytruda combo trial | ||
| Di | Incyte doubles down on atopic dermatitis push with trial win for JAK med Jakafi | ||
| Di | Allergan unveils new Botox plant ahead of $63B AbbVie merger | ||
| Di | J&J CEO on the stand: Gorsky faces questions about well-timed stock trade, talc testing | ||
| Di | Shkreli faces new FTC, N.Y. crackdown for allegedly thwarting Daraprim generics | ||
| Di | J&J's ketamine depression drug Spravato spurned by England's influential cost watchdogs | ||
| Mo | Merck KGaA antes up €250M to bridge R&D with manufacturing | ||
| Mo | FDA faults Biocon's biosimilars plant during preapproval review | ||
| Mo | Eli Lilly, Incyte's Olumiant notches another atopic dermatitis win. But can it fight Dupixent? | ||
| Mo | Krystal Biotech investing up to $90M on facility for its gene therapies | ||
| Mo | China repurposes AbbVie HIV drug as Big Pharma rallies to combat deadly coronavirus | ||
| Mo | New sickle cell drugs from Novartis, GBT need big discounts: ICER draft | ||
| Mo | AstraZeneca's Brilinta fends off repeat strokes better than solo aspirin, trial shows | ||
| Mo | FiercePharmaPolitics-PhRMA, BIO jack up lobbying spend as political squeeze intensifies | ||
| Mo | AbbVie, Allergan sell 3 drugs to win U.S. antitrust clearance-and send AstraZeneca, Nestlé into new realms | ||
| Mo | Call for FDA to withdraw preterm birth drug divides doctors and insurers | ||
| Fr | NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions | ||
| Fr | Pfizer challenges Roche blockbusters with 3 biosim launches at discounts from 22% to 24% | ||
| Fr | Roche's Tecentriq flops in postsurgery muscle-invasive bladder cancer | ||
| Fr | Insys founder Kapoor gets 5.5 years in prison for role in Subsys kickback scheme | ||
| Fr | Epizyme scores FDA nod for rare cancer med Tazverik, but prices it for a future indication: analyst |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
